ISSN: 2578-4803
Authors: Mittu B*
A significant pathogen that affects both humans and animals is linked to a variety of illnesses. Treatment for pathogenic strains that are resistant to nearly all existing medicines is a therapeutic problem due to the advent of antibiotic resistance. Globally, developing new antimicrobial strategies is currently of utmost importance. The most varied class of antimicrobial peptides produced by bacteria are called bacteriocins. Bacteriocins are peptides that are synthesized ribosomally and exhibit strong antibacterial activity, typically against bacteria that share phylogenetic relationships with the strain that produces them. Several bacteriocins that exhibit inhibitory activity against harmful bacteria both in vitro and in vivo have been identified from commensal coagulase-negative staphylococci. These bacteriocins are excellent candidates for new therapeutic antimicrobials due to their unique modes of action, effectiveness against bacteria resistant to antibiotics, and capacity to target the production of biofilms. The identification and classification of bacteriocins will progress with the application of genome-mining technologies. The potential of staphylococcal-derived antimicrobial peptides as cutting-edge therapies for infectious strains is covered in this article.
Keywords: Bacteriocins; Antimicrobial Peptides; Staphylococcus Aureus; Pahogens
